e-learning
resources
ERJ
2022
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effects of nintedanib by inclusion criteria for progression of interstitial lung disease
Toby M. Maher, Kevin K. Brown, Michael Kreuter, Anand Devaraj, Simon L.F. Walsh, Lisa H. Lancaster, Elizabeth A. Belloli, Maria Padilla, Juergen Behr, Rainer-Georg Goeldner, Kay Tetzlaff, Rozsa Schlenker-Herceg, Kevin R. Flaherty
Source:
Eur Respir J, 59 (2) 2004587; 10.1183/13993003.04587-2020
Journal Issue:
February
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Toby M. Maher, Kevin K. Brown, Michael Kreuter, Anand Devaraj, Simon L.F. Walsh, Lisa H. Lancaster, Elizabeth A. Belloli, Maria Padilla, Juergen Behr, Rainer-Georg Goeldner, Kay Tetzlaff, Rozsa Schlenker-Herceg, Kevin R. Flaherty. Effects of nintedanib by inclusion criteria for progression of interstitial lung disease. Eur Respir J, 59 (2) 2004587; 10.1183/13993003.04587-2020
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Management of severe community acquired pneumonia – ERS guidelines
Panel discussion on genetics in pulmonary fibrosis
Related content which might interest you:
Effect of pirfenidone on IPF progression
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Effect of baseline composite physiologic index on benefit of nintedanib in IPF
Source: International Congress 2016 – IPF treatment I
Year: 2016
Effects of nintedanib on progression of ILD in patients with fibrosing ILDs and a progressive phenotype: further analyses of the INBUILD trial
Source: Virtual Congress 2020 – What is new in interstitial lung diseases of known origin?
Year: 2020
Effect of baseline statin use on benefit of nintedanib
Source: International Congress 2016 – IPF treatment II
Year: 2016
The effect of nintedanib compared to pirfenidone on proliferation of lung fibroblasts from patients with IPF
Source: International Congress 2015 – Interstitial lung diseases II
Year: 2015
Clinical use of interstitial lung disease guidelines
Source: Eur Respir Mon; 2009: 46: 386–395
Year: 2009
Predictors of progression in systemic sclerosis patients with interstitial lung disease
Source: Eur Respir J, 55 (5) 1902026; 10.1183/13993003.02026-2019
Year: 2020
Clinical characteristics of patients with unclassifiable interstitial lung disease
Source: International Congress 2015 – New insights into IIPs
Year: 2015
Clinical trials in interstitial lung disease
Source: Eur Respir Mon; 2009: 46: 67–84
Year: 2009
Effect of baseline FVC on lung function decline with nintedanib in patients with IPF
Source: International Congress 2015 – Treatment of IPF
Year: 2015
The effect of pirfenidone on impaired lung function in patients with idiopathic pulmonary fibrosis (IPF) from Czech IPF registry
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Different definitions of pulmonary hypertension in interstitial lung disease: a prognostic evaluation.
Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases
Year: 2020
Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease III
Year: 2013
Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage
Source: ERJ Open Res, 5 (2) 00127-2018; 10.1183/23120541.00127-2018
Year: 2019
Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing extents of lung fibrosis: the SENSCIS trial
Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new?
Year: 2019
Long-term treatment with nintedanib in patients with IPF: An update from INPULSIS®-ON
Source: International Congress 2016 – IPF treatment II
Year: 2016
Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Effects of pulmonary rehabilitation in patients with interstitial lung disease (ILD)
Source: Annual Congress 2009 - New treatment and outcome measures for pulmonary rehabilitation
Year: 2009
Nintedanib in patients with chronic fibrosing interstitial lung diseases with progressive phenotype: the INBUILD trial
Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension
Year: 2019
Safety and tolerability of pirfenidone (PFD) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD)–The LOTUSS study
Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept